Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267846 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06267846 is a Phase 2 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 73 participants.
The verdict
NCT06267846, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG NBI-1070770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2025-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06267846
The ClinicalTrials.gov registry entry for NCT06267846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06267846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06267846 about?
NCT06267846 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder". To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
What is the current status of trial NCT06267846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2024-03-20. Estimated completion is 2025-09-11.
What interventions are being tested in trial NCT06267846?
The interventions under investigation include: Placebo (DRUG), NBI-1070770 (DRUG).
Who is sponsoring clinical trial NCT06267846?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.